68 Healthcare stocks rated Strong Buy (Nov 2026)
68 Healthcare stocks rated Strong Buy by the Lician Quant rating as of Nov 4, 2026, including Regeneron Pharmaceuticals Inc (REGN), Veeva Systems Inc Class A (VEEV), Neurocrine Biosciences Inc (NBIX). Quant rating 4.50 or higher (Strong Buy) against sector peers.
Open this screen in the full screener to add filters, sort by any factor and save it.
68 stocks · Strong Buy · Healthcare
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1QTTBQ32 Bio Inc | 5.00Strong Buy | A+ | — | A+ | B | A | $206M | 6.1 | — | — | 57.9% | Nov 12 |
| 2AVAHAveanna Healthcare Holdings Inc | 4.99Strong Buy | A | A- | B+ | A | A+ | $2.9B | 10.6 | +19.5% | — | 10.2% | Nov 12 |
| 3CDNACareDx Inc | 4.98Strong Buy | C+ | B+ | A+ | A+ | A+ | $3.6B | 32.2 | +34.4% | — | 13.6% | — |
| 4HALOHalozyme Therapeutics Inc | 4.97Strong Buy | C | B+ | A+ | A+ | A+ | $14.7B | 35.4 | +41.2% | — | 11.2% | Nov 5 |
| 5OSCROscar Health Inc | 4.97Strong Buy | — | A | A- | A | B- | — | — | +42.8% | — | — | Nov 5 |
| 6BTSGBrightSpring Health Services, Inc. Common Stock | 4.96Strong Buy | A- | A- | B- | A | — | $11.6B | 28.4 | +22.9% | — | 12.0% | — |
| 7REGNRegeneron Pharmaceuticals Inc | 4.95Strong Buy | B+ | C+ | A+ | A | A | $103B | 21.5 | +18.6% | — | 2.1% | — |
| 8PACSPACS Group, Inc. | 4.94Strong Buy | B+ | A | A- | A | B | $7.6B | 28.1 | +16.6% | — | — | — |
| 9CONConcentra Group Holdings Parent, Inc. | 4.94Strong Buy | A- | B- | A- | A+ | B | $5.0B | 25.4 | +14.0% | 0.99% | 3.1% | Nov 5 |
| 10ASTHAstrana Health Inc | 4.93Strong Buy | A+ | A | B | C | A+ | $1.8B | 44.0 | +58.9% | — | 8.0% | Nov 5 |
| 11ARQTArcutis Biotherapeutics Inc | 4.92Strong Buy | C+ | A+ | A- | A- | B+ | $3.9B | 137.4 | +76.1% | — | 23.9% | Nov 4 |
| 12GMEDGlobus Medical | 4.91Strong Buy | A+ | A- | A | C | A- | $8.6B | 16.1 | +19.7% | — | 7.3% | Nov 5 |
| 13HRMYHarmony Biosciences Holdings | 4.91Strong Buy | A+ | B | A | C+ | A- | $2.2B | 12.3 | +24.3% | — | — | Nov 4 |
| 14NUTXNutex Health Inc | 4.90Strong Buy | A+ | A- | A | B- | B- | $1.4B | 7.3 | +6.9% | — | — | Nov 5 |
| 15KNSAKiniksa Pharmaceuticals Ltd | 4.89Strong Buy | B- | A+ | A | A+ | C | $4.1B | 37.7 | +58.2% | — | 9.6% | — |
| 16INVAInnoviva Inc | 4.89Strong Buy | A+ | B+ | A+ | C- | A- | $1.5B | 4.3 | +18.8% | — | 10.5% | Nov 4 |
| 17PTGXProtagonist Therapeutics Inc | 4.88Strong Buy | C | A- | A+ | B+ | A | $9.4B | 113.0 | +34.8% | — | — | Nov 5 |
| 18NBIXNeurocrine Biosciences Inc | 4.87Strong Buy | B+ | A | A+ | B- | B | $14.7B | 21.0 | +38.0% | — | 6.6% | — |
| 19OMEROmeros Corporation | 4.86Strong Buy | C | — | — | A- | A+ | $1.2B | 9.6 | — | — | 20.4% | Nov 12 |
| 20VEEVVeeva Systems Inc Class A | 4.85Strong Buy | C+ | B | A+ | A | B+ | $50.6B | 49.9 | +16.5% | — | — | Nov 19 |
| 21PNTGPennant Group Inc | 4.85Strong Buy | A- | B+ | B+ | B+ | B+ | $1.4B | 43.7 | +37.9% | — | — | Nov 4 |
| 22ADUSAddus HomeCare Corporation | 4.84Strong Buy | A+ | B | B | B | A- | $2.3B | 21.7 | +15.9% | — | — | — |
| 23AMNAMN Healthcare Services Inc | 4.83Strong Buy | A+ | D+ | B- | A+ | A- | $1.6B | 14.9 | +24.0% | — | 10.0% | Nov 5 |
| 24MGTXMeiraGTx Holdings PLC | 4.82Strong Buy | A | A+ | A+ | D | B- | $897M | 11.4 | +948.3% | — | 17.6% | Nov 12 |
| 25RIGLRigel Pharmaceuticals Inc | 4.82Strong Buy | A+ | B+ | A+ | A | D- | $895M | 2.8 | +3.3% | — | 18.3% | Nov 5 |
Showing 25 of 68
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar
Strong Buy in other sectors
About this screen
- Which are the top Healthcare stocks rated Strong Buy?
- As of Nov 4, 2026, the highest ranked are Q32 Bio Inc (QTTB, rating 5.00); Aveanna Healthcare Holdings Inc (AVAH, rating 4.99); CareDx Inc (CDNA, rating 4.98); Halozyme Therapeutics Inc (HALO, rating 4.97); Oscar Health Inc (OSCR, rating 4.97). 68 stocks pass the screen in total.
- What does this screen look for?
- Quant rating 4.50 or higher (Strong Buy) against sector peers.
- How is the Lician Quant rating calculated?
- Each stock gets five factor grades (Valuation, Growth, Profitability, Momentum, EPS Revisions) from A+ to F by ranking its metrics against the other stocks in its sector. The rating (1.00 to 5.00) is the equal-weight average of the factor scores, re-ranked within the sector: 4.50 and up is Strong Buy, 3.50 Buy, 2.50 Hold, 1.50 Sell, below that Strong Sell.
- How often is the list updated?
- After every US trading day, from SEC filings, EODHD prices and analyst estimates; this list is from the quant run of Nov 4, 2026. Short interest follows FINRA's twice-monthly settlement dates.